Dashboard
Manage Tickers

NGNENeurogene Inc.

Nasdaq neoleukin.com


$ 35.23 $ -1.42 (-3.87 %)    

Monday, 09-Sep-2024 15:42:38 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 453.90 $ 1.37 (0.3 %)
DIA $ 409.23 $ 1.90 (0.47 %)
SPY $ 546.10 $ 1.43 (0.26 %)
TLT $ 99.97 $ 0.59 (0.59 %)
GLD $ 231.49 $ 0.23 (0.1 %)
$ 35
$ 36.65
$ 35.02 x 100
-- x --
$ 34.77 - $ 37.58
$ 12.49 - $ 53.00
89,332
na
9.69M
$ 3.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-20-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-09-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-14-2016 12-31-2015 10-K
36 11-10-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 11-04-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
HC Wainwright & Co. Maintains Buy on Neuro...
08/12/2024 10:37:01

HC Wainwright & Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target fro...

Core News & Articles
Neurogene Q2 2024 GAAP EPS $(1.09) Misses ...
08/09/2024 11:35:45

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.06) b...

Core News & Articles
Neurogene's NGN-401 Receives Regenerative ...
08/07/2024 11:36:55

Core News & Articles
Neurogene To Be Added To Russell 3000 Ind...
07/01/2024 11:35:21

Core News & Articles
BMO Capital Initiates Coverage On Neurogen...
06/27/2024 09:17:12

BMO Capital analyst Keith Tapper initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price ...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
06/20/2024 12:05:58

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Neur...
06/20/2024 10:36:34

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

why-quantum-shares-are-trading-lower-by-45-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Quantum Shares Are Trading Lower By 45...
06/18/2024 17:39:53

Core News & Articles
Neurogene Reports First Patient Dosed In H...
06/18/2024 13:28:02

High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data...

Core News & Articles
Baird Initiates Coverage On Neurogene with...
06/11/2024 09:18:01

Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target ...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Neur...
06/04/2024 10:38:09

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

Core News & Articles
Neurogene Says NGN-401 Gene Therapy For Re...
06/03/2024 11:45:49

As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to furth...

Core News & Articles
HC Wainwright & Co. Maintains Buy on Neuro...
05/13/2024 14:56:51

HC Wainwright & Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target fro...

Core News & Articles
Neurogene Q1 EPS $(1.00) Misses $(1.14) Es...
05/10/2024 11:36:13

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.14) by ...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Neur...
05/08/2024 13:28:41

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $55 price target.

Core News & Articles
Neurogene Announced Initial Safety And Tol...
05/07/2024 10:21:11

These data were presented during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. 

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Neur...
05/03/2024 20:11:23

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $55 price target.

Core News & Articles
Leerink Partners Initiates Coverage On Neu...
04/29/2024 12:45:24

Leerink Partners analyst Mani Foroohar initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces ...

Core News & Articles
Neurogene Reports Upcoming Presentation Of...
04/22/2024 20:38:00

The data show that the NGN-401 gene therapy candidate has been generally well-tolerated, and there have been no treatment-emerg...

Core News & Articles
William Blair Initiates Coverage On Neurog...
03/21/2024 10:06:07

William Blair analyst Sami Corwin initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION